Rankings
▼
Calendar
ALNY Q2 2019 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
$42B
Q2 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$45M
+49.5% YoY
Gross Profit
$40M
90.3% margin
Operating Income
-$236M
-528.4% margin
Net Income
-$219M
-490.9% margin
EPS (Diluted)
$-2.02
QoQ Revenue Growth
+34.3%
Cash Flow
Operating Cash Flow
$289M
Free Cash Flow
$267M
Stock-Based Comp.
$31M
Balance Sheet
Total Assets
$2.7B
Total Liabilities
$959M
Stockholders' Equity
$1.8B
Cash & Equivalents
$1.1B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$45M
$30M
+49.5%
Gross Profit
$40M
$30M
+35.0%
Operating Income
-$236M
-$192M
-22.8%
Net Income
-$219M
-$164M
-34.2%
Revenue Segments
Product
$38M
100%
Geographic Segments
UNITED STATES
$28M
74%
Non-US Or Europe
$10M
26%
← FY 2019
All Quarters
Q3 2019 →